Evidence map›Paper›PMID 40875102›Full record

ArticleHepatology international2025

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Masatsugu Ohara, Goki Suda, Risako Kohya, Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Joji Tani, Shinya Maekawa, Nobuyuki Enomoto, Makoto Chuma and 28 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors.

Masatsugu Ohara *Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Goki Suda *Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan. gsudgast@pop.med.hokudai.ac.jp.ORCID http://orcid.org/0000-0003-0098-9106
Risako KohyaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Yutaka YasuiDepartment of Gastroenterology, Hepatology Musashino Red Cross Hospital, Tokyo, Japan.
Kaoru TsuchiyaDepartment of Gastroenterology, Hepatology Musashino Red Cross Hospital, Tokyo, Japan.
Masayuki KurosakiDepartment of Gastroenterology, Hepatology Musashino Red Cross Hospital, Tokyo, Japan.
Joji TaniDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Shinya MaekawaDepartment of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Kofu, Japan.
Nobuyuki EnomotoDepartment of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Kofu, Japan.
Makoto ChumaGastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Manabu MorimotoGastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Shun KanekoDepartment of Gastroenterology and Hepatology, Institute of Science Tokyo (Science Tokyo), Tokyo, Japan.
Mina NakagawaDepartment of Gastroenterology and Hepatology, Institute of Science Tokyo (Science Tokyo), Tokyo, Japan.
Yasuhiro AsahinaDepartment of Gastroenterology and Hepatology, Institute of Science Tokyo (Science Tokyo), Tokyo, Japan.
Atsumasa KomoriHepatology Division, NHO Nagasaki Medical Centre, Ōmura, Japan.
Yuki KugiyamaHepatology Division, NHO Nagasaki Medical Centre, Ōmura, Japan.
Masaru BabaCentre for Gastroenterology and Hepatology, Japan Community Healthcare Organisation Hokkaido Hospital, Sapporo, Japan.
Akihisa NakamuraDepartment of Gastroenterology, Kitami Red Cross Hospital, Kitami, Japan.
Jun ItoDepartment of Gastroenterology and Hepatology, NHO Hokkaido Medical Centre, Sapporo, Japan.
Ren YamadaKushiro Rosai Hospital, Kushiro, Japan.
Shunichi HosodaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Yoshiya YamamotoDepartment of Gastroenterology and Hepatology, Hakodate Municipal Hospital, Hakodate, Japan.
Sonoe YoshidaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Takuya ShoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Takashi SasakiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Tomoka YodaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Akimitsu MenoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Naohiro YasuuraDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Qingjie FuDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Zijian YangDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Osamu MaeharaLaboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Shunsuke OhnishiLaboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Yoshimasa TokuchiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Takashi KitagatayaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Naoki KawagishiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Masato NakaiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Koji OgawaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan.

Funding

the Japan Agency for Medical Research and Development (AMED) grant numbers JP25fk0210126the Japan Agency for Medical Research and Development (AMED) JP24fk0210121the Japan Agency for Medical Research and Development (AMED) JP25fk0210123the Japan Agency for Medical Research and Development (AMED) JP25fk0210142the Japan Agency for Medical Research and Development (AMED) JP25fk0210143the Japan Agency for Medical Research and Development (AMED) JP25fk0210157the Japan Agency for Medical Research and Development (AMED) JP25fk0210172 JP25fk0210174the Japan Agency for Medical Research and Development (AMED) JP25fk0310535the Japan Agency for Medical Research and Development (AMED) JP25fk0310543the Japan Agency for Medical Research and Development (AMED) JP25fk0310545the Japan Agency for Medical Research and Development (AMED) JP25fk0310551
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality. Although the atezolizumab/bevacizumab regimen demonstrated impressive efficacy in the IMbrave150 clinical trial, long-term outcomes, particularly 3-year overall survival (OS), remain unestablished because of limited follow-up. Long-term outcomes have been reported for the tremelimumab/durvalumab combination, highlighting the need for comparable data on atezolizumab/bevacizumab. We aimed to elucidate the 3-year OS in patients with unresectable HCC (uHCC) treated with atezolizumab plus bevacizumab.

methodsThis retrospective multicenter study included patients with uHCC who received atezolizumab/bevacizumab. Among the 506 patients treated at the participating institutions, only those who initiated therapy between October 2020 and January 2022 were included. Comprehensive clinical, laboratory, and imaging data were collected, and the patients were followed up until March 2025.

resultsA total of 257 patients were analyzed, with a median follow-up of 48.23 months (range, 36.23-53.60 months). The 2- and 3-year OS rates were 39.2% and 25.3%, respectively. Among patients meeting the IMbrave150 criteria, the 3-year OS rate was 31.6%. Multivariate regression analysis identified baseline alpha-fetoprotein level > 116 ng/mL (odds ratio [OR] 0.41; 95% confidence interval [CI] 0.20-0.84; p = 0.015) and modified albumin-bilirubin grade 1-2a (OR 2.50; 95% CI 1.18-5.32; p = 0.017) as significant factors associated with 3-year OS.

conclusionsIn a real-world setting, the 3-year OS for uHCC patients treated with atezolizumab/bevacizumab was 25.3%, rising to 31.6% among those meeting the IMbrave150 criteria. Survival outcomes underscore the clinical value of atezolizumab/bevacizumab in improving long-term prognosis and guiding first-line treatment decisions for patients with unresectable HCC.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabBiomarkerCancerDisease progressionLiverLong-term survivalMalignancyOncology outcomesReal-world evidenceRetrospective studyTreatment efficacy

Identifiers

PMID40875102

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.